Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGENFree Report) in a report published on Friday morning. The firm issued a sell rating on the stock.

Oragenics Stock Down 2.8 %

Shares of NYSE OGEN opened at $1.40 on Friday. The stock has a 50 day moving average price of $3.09. Oragenics has a twelve month low of $1.34 and a twelve month high of $7.74.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the company’s stock worth $171,000 after buying an additional 37,338 shares in the last quarter. Renaissance Technologies LLC raised its stake in Oragenics by 24.4% during the fourth quarter. Renaissance Technologies LLC now owns 288,398 shares of the company’s stock valued at $30,000 after purchasing an additional 56,498 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock valued at $45,000 after purchasing an additional 110,119 shares during the last quarter. 2.07% of the stock is currently owned by institutional investors.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Articles

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.